Tavros achieves milestones in collaboration with Bayer’s Vividion

Precision oncology platform company Tavros Therapeutics has achieved two milestone payments in its collaboration with the Bayer (BAYN: DE) subsidiary Vividion Therapeutics.

The payments were triggered by the successful achievement of predefined milestones, underscoring the progress of the strategic collaboration to discover and develop targeted oncology therapies.

"Capable of addressing cancer-causing proteins that have eluded traditional small molecule drugs"Eoin McDonnell, chief executive and co-founder of Noth Carolina-based Tavros, said: “These milestones signify crucial advancements in our collaboration with Vividion. They highlight the strength of our precision oncology platform, EVOLVE, and Vividion’s commitment to exploring innovative treatment options across various tumor types to maximize patient benefit.”